Schrodinger(US:SDGR)2026-02-25 22:32Financial Data and Key Metrics Changes - The company reported $256 million in revenue for 2025, reflecting a 23% growth compared to the previous year [12] - Software revenue was $199.5 million, with an annual contract value (ACV) of $198.5 million, showing strong growth from commercial customers [12][16] - Drug discovery revenue more than doubled to $56.4 million, indicating successful execution across collaborative programs [12][13] - The net loss for the year was $103 million, an improvement from a net loss of $187 million in 2024 [14] Business Line Data and Key Metrics Changes - Software revenue increased by 11%, while drug discovery revenue saw significant growth due to successful collaborations [12][13] - The software gross margin decreased to 74% from 80% in 2024, attributed to higher costs associated with contribution revenue from grants [13] - The company achieved a 96% gross dollar retention rate, indicating strong renewal performance among existing customers [18] Market Data and Key Metrics Changes - The company expanded its top 20 pharma relationships, with ACV for this cohort growing by 15% [16] - The materials science business grew from $15 million to $17 million as new capabilities were introduced [19] - The company is targeting additional budgets within existing customers and unlocking opportunities in large markets such as biologics and toxicology [11] Company Strategy and Development Direction - The company aims for 10%-15% software ACV growth and plans to transition approximately 75% of software revenue to hosted contracts by 2028 [10][24] - The strategic focus includes accelerating the growth of the software business and advancing the therapeutics portfolio [3][10] - The company is leveraging AI and computational methods to enhance drug and materials discovery, positioning itself as a leader in the field [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial and operational goals, despite a challenging macro environment [34] - The company anticipates continued demand for its technology driven by the adoption of AI and the expansion of its computational platform [54] - The outlook for 2026 includes expectations for ACV in the range of $218 million to $228 million, reflecting 10%-15% growth [24][25] Other Important Information - The company is transitioning to a hosted model, which will result in more predictable revenue but may compress gross margins in the near term [20][22] - The predictive toxicology solution is expected to contribute to growth, with positive feedback from beta testing [40][61] - The company maintains a strong balance sheet with over $400 million in cash, supporting its growth initiatives [12][26] Q&A Session Summary Question: Impact of transitioning to hosted contracts on profitability - Management indicated that the transition to hosted contracts is expected to support long-term profitability goals, with a focus on maintaining expense discipline [38][39] Question: Growth expectations from new products like Predictive Tox - Management confirmed that new products, including Predictive Tox, are expected to contribute to growth, with both existing and new customers likely to adopt these solutions [40][61] Question: Customer engagement with the transition to hosted solutions - Management noted that customers are increasingly preferring hosted deployments, which allow for faster deployment and enhanced support [50][51] Question: Expectations for ACV growth and its relation to revenue - Management clarified that ACV reflects the value of contracts, while revenue recognition may vary due to the transition to hosted contracts [73][74] Question: Biotech funding environment and its impact on growth - Management anticipates a recovery in the biotech sector over the next three years, which could positively influence growth [69]